Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2014-02-04 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 92% confidence The document is a press release dated February 4, 2014, announcing a commercialization agreement between Sosei and FUJIFILM Pharma for Loramyc®, a product developed by BioAlliance Pharma. It details partnership updates, clinical trial progress (Phase III), and future commercial plans. This type of announcement, focusing on strategic business developments, partnerships, and pipeline updates, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific governance/insider filing, it fits best as an Earnings Release (ER) which often includes key business updates alongside financial highlights, or potentially a Regulatory Filing (RNS) if it were purely informational. Given the context of business updates and partnership news, ER is a strong candidate, but since it is a general press release about a business deal rather than explicit quarterly results, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for non-standard, material news releases that aren't explicitly defined elsewhere. However, many such press releases announcing material business developments are classified as ERs even if they don't contain the full quarterly numbers. Given the content focuses heavily on the drug development and commercialization strategy, it is a material business update. I will classify it as an Earnings Release (ER) as these often contain strategic business updates, but RNS is a close second. Given the lack of explicit financial figures for a period, RNS is safer as a general announcement.
2014-02-04 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated January 23, 2014, announcing that BioAlliance Pharma SA's product, Validive®, received a Fast Track designation from the FDA for treating oral mucositis. It discusses clinical trial progress (Phase II enrollment nearing completion) and future data release timelines. This type of announcement, focusing on regulatory milestones, clinical development updates, and pipeline progress, is characteristic of general investor communications that do not fit the specific definitions of a formal financial report (like 10-K, IR, or ER). Since it is a specific announcement about a regulatory event (FDA designation) and pipeline progress, it is best classified as a general Regulatory Filing (RNS) as it doesn't match the more specific categories like Capital/Financing (CAP), Earnings Release (ER), or Legal Proceedings (LTR). It is not a report itself, but an announcement.
2014-01-23 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated January 23, 2014, announcing that BioAlliance Pharma's drug, Validive®, received 'Fast Track' status from the FDA for treating oral mucositis. This type of announcement, detailing a regulatory milestone, clinical development update, and general company news, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change, and it focuses on key operational/regulatory news, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally as a Regulatory Filing (RNS) for non-standard announcements. Given the content is a specific, non-financial operational update (FDA status), and it doesn't explicitly state it's an attachment to a larger report (ruling out RPA), RNS is a strong candidate. However, many companies issue these types of operational updates alongside or in lieu of a formal ER when major news breaks outside of standard reporting cycles. Since it is a significant announcement about product development and regulatory progress, and it is not a standard financial report, I will classify it as a Regulatory Filing (RNS) as it is a general regulatory/operational announcement that doesn't fit the other specific categories like DIRS, DIV, or MANG. It is not a formal Earnings Release (ER) which typically focuses on revenue/profit figures.
2014-01-23 French
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document explicitly discloses the "total number of voting rights and number of shares in the capital" as of a specific date (December 31, 2013), citing requirements from the French Commercial Code and the AMF (Autorité des Marchés Financiers). This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing requirement, often related to capital structure or general corporate status updates. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It most closely aligns with a general regulatory announcement concerning share capital structure, which fits best under the broad category of Regulatory Filings (RNS) or potentially Share Issue/Capital Change (SHA). Since it is a mandatory disclosure of the total number of shares/rights, and not an announcement of a transaction (POS) or a change in ownership threshold (MRQ), RNS serves as the most appropriate general regulatory filing category for this specific type of statutory disclosure that doesn't fit a more specific financial report type. Given the short length and statutory nature, RNS is preferred over SHA, which usually implies an active issuance or buyback.
2014-01-13 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital au 31 décembre 2013" (Information relating to the total number of voting rights and shares comprising the capital as of December 31, 2013). It explicitly cites French regulatory articles (Code de commerce and Règlement général de l'Autorité des Marchés Financiers) requiring the disclosure of the total number of voting rights and shares outstanding as of a specific date (December 31, 2013). This type of periodic disclosure regarding the total share capital and voting rights is a specific regulatory requirement, often related to capital structure updates or mandatory periodic reporting. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit as it deals directly with the number of shares and voting rights, which are fundamental components of the capital structure. It is not a general earnings release (ER), an interim report (IR), or a full annual report (10-K).
2014-01-13 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated December 4, 2013, announcing that BioAlliance Pharma SA has received authorization (IND approval from the FDA and green light from the German health agency) to start its Phase III ReLive clinical trial for Livatag® in the US and Germany. This announcement details progress in clinical development, regulatory milestones, and future recruitment timelines. It is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a transcript (CT). It is a specific update regarding clinical trial progress and regulatory clearance for a drug candidate. While it contains information relevant to investors, it is not a formal Investor Presentation (IP) or a Management Discussion & Analysis (MDA). Since it is a specific announcement about regulatory/clinical progress that doesn't fit the other specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, as it is a material, non-financial regulatory update released to the public, or potentially a general announcement if RNS is reserved for filings to exchanges only. Given the options, RNS serves as the best catch-all for significant, non-standard regulatory/clinical news releases. However, since the content is highly focused on clinical trial progress and regulatory approvals, and it is a press release format, RNS is the most appropriate fit among the provided codes for a significant, non-periodic corporate announcement.
2013-12-04 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.